Showing 631-640 of 21412 results for "".
- Exploring the Dual Benefits of GLP-1 Receptor Agonists in Diabetes and Cancer Risk Reductionhttps://reachmd.com/news/exploring-the-dual-benefits-of-glp-1-receptor-agonists-in-diabetes-and-cancer-risk-reduction/2474893/As obesity and diabetes converge to amplify cancer risk in routine practice, clinicians must note that this indica
- Women Remain Underrepresented in Revascularization Trials—Can Cardiology Leaders Reverse That Trend?https://reachmd.com/news/women-remain-underrepresented-in-revascularization-trialscan-cardiology-leaders-reverse-that-trend/2467121/Another ongoing challenge is the fact that women tend to have more day-to-day burdens related to “childcare and family responsibilities,” making it harder for them to agree to the long-term commitments associated with clinical trial participation following PCI or CABG.
- A New Era in Obesity and Diabetes Management: GLP-1 Receptor Agonistshttps://reachmd.com/news/a-new-era-in-obesity-and-diabetes-management-glp-1-receptor-agonists/2476047/Innovative GLP-1 receptor agonists are heralding a new frontier in obesity and diabetes management, offering potent weight loss via appetite modulation but demanding vigilant attention to gastrointestinal discomfort and muscle weakness. The ability of GLP-1 drugs to
- AI-Driven Tool Offers Contactless Screening for Hypertension and Diabeteshttps://reachmd.com/news/ai-driven-tool-offers-contactless-screening-for-hypertension-and-diabetes/2468604/A new AI-powered tool has shown promise for fast, non-invasive screening of high blood pressure and diabetes, potentially paving the way for at-home, no-contact monitoring. Presented as a preliminary study at the American Heart Association’s Scientific Sessions 2024, this system uses high-speed v
- GLP-1 Agonists Reduce Kidney Disease Risk, Offering Benefits Beyond Diabetes Managementhttps://reachmd.com/news/glp-1-agonists-reduce-kidney-disease-risk-offering-benefits-beyond-diabetes-management/2468701/A groundbreaking meta-analysis has revealed that glucagon-like peptide-1 (GLP-1) receptor agonists may be able to reduce the risk of kidney failure and cardiovascular events, even in individuals without diabetes. Published in The Lancet Diabetes & Endocrinology, the study evaluated o
- Non-COVID-19 Deaths Among People with Diabetes Jumped During Pandemic, Global Study Revealshttps://reachmd.com/news/non-covid-19-deaths-among-people-with-diabetes-jumped-during-pandemic-global-study-reveals/2456944/Non-COVID-19-related deaths among people with diabetes increased during the pandemic, as did the diabetes complication of sight loss, according to a global study review led by a University of Massachusetts Amherst public health researcher that examined the impacts of pandemic-related disruptions
- MicroRNA Expression in Gestational Diabetes Mellitus: Clinical Implicationshttps://reachmd.com/news/microrna-expression-in-gestational-diabetes-mellitus-clinical-implications/2474793/MicroRNAs, small non-coding RNAs that modulate gene expression, play a critical role in cellular processes. In obstetrics and gynecology, skewed microRNA profiles in GDM patients offer a distinct molecular signature, aiding in timely di
- Diabetes Increases the Risk of Failure in Spinal Fusion Procedureshttps://reachmd.com/news/diabetes-increases-the-risk-of-failure-in-spinal-fusion-procedures/2467306/
- Repurposing Diabetes Medication for Hydrocephalus Treatmenthttps://reachmd.com/news/repurposing-diabetes-medication-for-hydrocephalus-treatment/2475417/Managing hydrocephalus with shunts or endoscopic third ventriculostomy remains challenging due to high infection and obstruction rates and the lifelong management they demand. Against this backdrop of invasive intervention, a line of p
- Low IFN-α2 Avidity Linked to Neurologic Complications in COVID-19https://reachmd.com/news/low-ifn-2-avidity-linked-to-neurologic-complications-in-covid-19/2488554/Key Takeaways Among patients with severe COVID-19 and confirmed anti-type I interferon autoantibodies, low anti-IFN-α2 avidity was associated with more neurological complications than high avidity. The anti-IFN-ω signal pointed in the same direction but was not stati